P. Kent Hawryluk has bought stock on 5 days since Aug 2016

P. Kent Hawryluk (age 56) is the co-founder, President, Chief Executive Officer, and Director of MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on developing peptide therapeutics for endocrine and metabolic diseases.( He has served as CEO since January 2020 and as a director since April 2019, leading key milestones such as completing enrollment in the Phase 2 Avail trial for canvuparatide, positive Phase 1 results for MBX 1416, and planning an IND for MBX 4291 in Q2 2025.( Hawryluk owns approximately 2.52-5.69% of the company and received total compensation of $2.24M in the latest reported year.(

Hawryluk brings over 20 years of experience as a life sciences entrepreneur, leader, and investor.( His career highlights include co-founding and serving as Chief Business Officer at Avidity Biosciences (2013–2019), where he built RNA therapeutics and business development capabilities; co-founding and leading MB2 LLC as CEO (2014–2016), acquired by Novo Nordisk; and co-founding Marcadia Biotech as CBO and VP of Business Development (2006–2011), acquired by Roche.( He holds a B.A. from Princeton University, an M.B.A. from Northwestern University’s Kellogg School of Management, and an M.S. in Biology from Purdue University.( Additionally, he is a Partner at Twilight Venture Partners since 2003 and previously served as a director at Gemphire Therapeutics (2015–2019).(

Written by Perplexity from public sources.